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PCardiac Imaging
atients With Atrial Fibrillation and
ense Spontaneous Echo Contrast at High Risk
Prospective and Serial Follow-Up Over 12 Months With
ransesophageal Echocardiography and Cerebral Magnetic Resonance Imaging
eter Bernhardt, MD,* Harald Schmidt, MD,† Christoph Hammerstingl, MD,*
erndt Lüderitz, MD, PHD, FACC, FESC, FAHA,* Heyder Omran, MD, PHD†
onn, Germany
OBJECTIVES We sought to assess the prognosis of patients with atrial fibrillation (AF) and dense
spontaneous echo contrast (SEC) and to determine the incidence of cerebral embolism under
continued oral anticoagulation.
BACKGROUND Patients with AF and dense SEC have an increased risk of cerebral embolism. However, there
is little knowledge about the long-term fate and the rate of clinical silent cerebral embolism
under continued oral anticoagulation.
METHODS Between 1998 and 2001, all consecutive patients with AF and dense SEC were included in
the study. We performed serial and prospective transesophageal echocardiography, cranial
magnetic resonance imaging, and clinical examinations during a period of 12 months.
RESULTS A total of 128 patients with dense SEC and AF were included. The control group consisted
of 143 patients with faint SEC and AF. During the follow-up period, three patients (2%) had
cerebral embolism with neurologic deficits. A total of eight patients (6%) died due to embolic
events, and 19 (15%) patients had silent embolism, as documented on cerebral magnetic
resonance imaging. Patients with an event had significantly lower left atrial appendage peak
emptying velocities and more commonly had a history of previous thromboembolism and
denser SEC, as compared with patients without an event.
CONCLUSIONS Patients with AF and dense SEC have a high likelihood of cerebral embolism (22%) and/or
death, despite oral anticoagulation. Low peak emptying velocities of the left atrial appendage
and dense SEC are independent predictors of an event. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.0711807–12) © 2005 by the American College of Cardiology Foundation
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Eense spontaneous echo contrast (SEC) is found in 12% to
7% of patients with atrial fibrillation (AF), depending on
he patient population (1–5). Patients with AF and SEC
ave an increased risk of cerebral embolism (1,4,6).
See page 1813
However, there is little knowledge about the long-term
ate of patients with permanent AF and SEC, as well as the
ncidence of cerebral embolism in those patients. Cranial
agnetic resonance imaging (MRI) has a high accuracy for
etecting cerebral embolism. Furthermore, modern cranial
RI allows the detection of cerebral microembolism (7–
0). Therefore, we chose to monitor patients with dense SEC
y means of cerebral MRI during the follow-up period.
The aims of this study were: 1) to assess the long-term
ate of patients with dense SEC under continued oral
nticoagulation; 2) to evaluate the incidence of cerebral
From the *Department of Medicine—Cardiology, University of Bonn; and †St.
arien Hospital Bonn, Bonn, Germany. The study was supported by grant
ONFOR #0-707 from the University of Bonn.w
Manuscript received May 16, 2004; revised manuscript received November 3, 2004,
ccepted November 11, 2004.mbolism during a follow-up period of 12 months; and 3) to
etermine the predictors of cerebral embolism.
ETHODS
tudy patients. Between 1998 and 2001, all patients 18
ears of age with permanent nonvalvular AF and SEC were
ncluded in the study. Exclusion criteria were contraindica-
ion to cerebral MRI, transesophageal echocardiography
TEE), and oral anticoagulation; carotid artery stenosis
50%; valvular heart disease; and the inability to give
ritten, informed consent. Written, informed consent was
btained from all patients, and the study was approved by
he Institutional Review Board of the University of Bonn.
tudy protocol. Patients were subclassified into two
roups: patients with dense SEC (study patients) and
atients with faint SEC (control subjects). After all patients
ere examined clinically, we performed assessment of the
ardiovascular risk factors (arterial hypertension, smoking,
iabetes mellitus, dyslipoproteinemia, and a history of
revious embolism). A 12-lead surface electrocardiogram
as obtained. The follow-up time was presumed to be 12
onths.
chocardiographic studies. All studies were conducted
ith commercially available equipment (System V or Vivid
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Fate of High-Risk Patients With AF June 7, 2005:1807–12, GE, Milwaukee, Wisconsin). For TEE, a 1.7/3.4-MHz
lectronic transducer was used. The M-mode left atrial
LA) dimension and left ventricular ejection fraction
LVEF) were measured according to the recommendations
f the American Society of Echocardiography (11).
Transesophageal echocardiography was performed with a
.7-MHz multiplane electronic transducer, as previously
eported by our study group (12,13). Cine loops of the LA
nd left atrial appendage (LAA) were stored. The sample
olume of the pulsed Doppler was placed 1 cm into the
rifice of the LAA, and the profile of the velocities was
ecorded.
chocardiographic data analysis. Echocardiographic
valuations were performed by two independent observers
xamining the digitized images after the original examina-
ion. The images were displayed in random order without
linical information on the patient and analyzed by means of
he evaluation software provided by the manufacturer
Echopac, GE). Interobserver differences were resolved by a
hird observer.
The cine loops of the LA and LAA were examined for
hrombi and SEC. The degree of SEC was categorized as
eing either absent (0), mild (1), mild to moderate (2),
oderate (3), or severe (4), on the basis of the system
escribed by Fatkin et al. (14) (Fig. 1). The LAA area and
Abbreviations and Acronyms
AF  atrial fibrillation
INR  international normalized ratio
LA  left atrium/atrial
LAA  left atrial appendage
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MRI  magnetic resonance imaging
SEC  spontaneous echo contrast
TEE  transesophageal echocardiography
igure 1. Transesophageal echocardiography with dense spontaneous echow
ontrast (SEC). LA  left atrium; LAAv  left atrial appendage peak
mptying velocity.eak emptying velocities were measured as previously re-
orted (15).
nticoagulation. Patients without effective anticoagula-
ion at admission received intravenous weight-adjusted
nfractionated heparin (17 U/kg/h) during hospitalization;
urther dose adjustments were performed to achieve an
ctivated partial thromboplastin time ratio of 1.5 to 2.5
imes of the control value, which was presumed to be
ffective. Before discharge, all patients were transferred to
ral anticoagulation with phenprocoumon. The effective-
ess of anticoagulation was assessed by the international
ormalized ratio (INR) level. An INR 2.0 was defined as
therapeutic range. The target INR was 2.5.
ranial MRI. Magnetic resonance imaging was done at a
2-month follow-up from the admission and after 1, 3, 6,
nd 12 months. The MRI examinations were performed
ith a 1.5-T system (Gyroscan ACS-NT, Philips Medical
ystems, Eindhoven, the Netherlands). The imaging pro-
ocol included a diffusion-weighted, single-shot, spin echo
choplanar sequence (diffusion gradient b values of 0, 500,
nd 1,000 s/mm2, repetition time [TR] of 4,000 ms, echo
ime [TE/TEd] of 120 ms/85 ms, slice thickness of 6 mm,
nd matrix 101  256), turbo fluid-attenuated inversion
ecovery (FLAIR) (TR/TE 6,000/100 ms), and T2-
eighted turbo spin echo (TR/TE 3,700/90 ms) sequences.
he acquisition time for the diffusion-weighted sequences
as 36 s (Fig. 2).
Diffusion-weighted images were acquired with diffusion
radients applied in three orthogonal directions. All MRI
tudies were evaluated by experienced consultant radiolo-
ists blinded to the neurologic status and procedure.
The MRI scans of the brain were evaluated for the
resence of focal diffusion abnormalities (bright lesions in
he diffusion-weighted image) in a pattern consistent with
mbolic lesions (i.e., cortical or subcortical localization or in
he vascular territory of perforating arteries). Diffuse alter-
tions in the diffusion-weighted sequence or a pattern of
atershed ischemia were not considered to be embolic types
f lesions. Number, size (5, 5 to 10, or 10 mm), and
ascular territory of all focal diffusion abnormalities were
ecorded.
In patients who showed a focal diffusion abnormality, a
ollow-up MRI, including T2-weighted, turbo spin echo,
nd fluid-attenuated inversion recovery sequences was per-
ormed after three months to define the presence or absence
f a subsequent infarct at the location of the diffusion
bnormality.
eurologic examination. Patients underwent neurologic
ssessments during a 12-month follow-up period at admis-
ion and after 1, 3, 6, and 12 months. The assessments were
one by a Board-certified neurologist. A neurologic com-
lication was defined as any new cranial nerve, motor, or
ensory deficiency, reflex change, pyramidal sign, or occur-
ence of mental alteration.
ltrasound of the cerebral arteries. All patients under-
ent ultrasound examination (HDI 3000, ATL, Bothell,
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June 7, 2005:1807–12 Fate of High-Risk Patients With AFashington) at admission and after 1, 3, 6, and 12 months
or detection of atherosclerotic lesions of the carotid arteries.
onsidering all information from B-mode, color Doppler,
nd Doppler ultrasound, stenoses of the common or internal
arotid artery were measured as a reduction of the luminal
rea, according to established criteria. All patients with
tenoses 50% were excluded from the study.
tatistical analysis. Data are reported as the mean value 
D. Continuous variables between groups were compared
y a t test for unpaired observations. Nominal data were
ompared by the Fisher exact test. Categorial data (degree
f SEC) were compared by the Wilcoxon signed rank test
or matched pairs. In all cases, a p value 0.05 was
onsidered statistically significant. The 95% confidence
ntervals are given.
ESULTS
atients. A total of 293 patients with SEC and permanent
F were screened for enrollment in the study. Twenty-two
atients were excluded due to pacemaker insertion and/or
nability to keep follow-up visits. The study group consisted
f 128 patients with dense SEC, and 143 patients with faint
EC comprised the control group. Patient data are provided
n Table 1. Eighty-eight study patients (69%) received oral
nticoagulation before inclusion into the study. At the index
dmission, 18 patients (14%) in the study group had a
istory of a previous embolism, and six patients (5%) had
eurologic deficits. Multivariate analysis of atherosclerotic
isks factors (diabetes, hypertension, smoking, hypercholes-
erolemia) and left ventricular (LV) dysfunction (LVEF
50%) shows patients with dense SEC as having a higher
igure 2. Cerebral magnetic resonance imaging scan in (A) T2- and (B)
iffusion-weighted imaging with (arrow) a cerebral lesion after an embolic
vent.
able 1. Patient Characteristics (n  271)
ge (yrs) 62.5  11.3*
ender (male) 186 (69%)
revious thromboembolism 41 (15%)
iabetes mellitus 49 (18%)
moking 112 (41%)
ypertension 143 (53%)
ypercholesterolemia (220 mg/dl) 154 (57%)
mbolism during follow-up 33 (12%)Mean value  SD.
L
vncidence of these risk factors, as compared with patients
ith faint SEC (110 [86%] vs. 104 [73%], p  0.01). Table
provides patient data. Figure 3 shows the Kaplan-Meier
raph for the combined end point (death and embolism)
uring the observation period.
chocardiography. Measurements of LV and LA dimen-
ions, LVEF, and LAA peak emptying velocities are given
n Table 2. At the index admission, the mean SEC degree
as 2.5  0.9, and the mean peak emptying velocity of the
AA was 0.27  0.15 m/s. When comparing SEC degree
nd LAA emptying velocities with the Wilcoxon signed
ank test, there is a significant match (p  0.0001).
nterobserver agreement for SEC score was kappa  0.87
nd for LAA emptying velocities kappa  0.92. Twelve
atients (9%) had a patent foramen ovale. Ten patients had
ortic plaques4 mm, and 86 patients had plaques4 mm.
one of the patients had mobile aortic atheroma. Patients
ith and without aortic plaque 4 mm did not differ in
erms of the incidence of embolic events. None of the
atients had thrombi in the LA or LAA at entry in the
tudy or during the observation period. Echocardiographic
ata are listed in Table 2.
ranial MRI and neurologic examination. Ten study
atients had old focal diffusion abnormalities at the index
dmission. During the 12-month follow-up period, 22
17%) of 128 patients manifested acute cerebral diffusion
bnormalities in a pattern consistent with embolic lesions.
he size of the embolic lesions was 5 mm in 17 lesions, 5
o 10 mm in 3 lesions, and 10 mm in 2 lesions. The
ffected vascular territories were superficial middle cerebral
igure 3. Kaplan-Meier graph for the combined end point (death and
mbolism) during the 12-month observation period.
able 2. Echocardiographic Data
AV (cm3) 99  71
VVD (cm3) 126  38
VEF (%) 56  14
EC (grade) 1.9  0.9
AAV (m/s) 0.37  0.18
AAV 0.2 m/s 35 (13%)
ersistent foramen ovale (n) 26 (10%)
ata are presented as the mean value  SD or number (%) of patients.
LAAV  left atrial appendage peak emptying velocity; LAV  left atrial volume;VEF  left ventricular ejection fraction; LVVD  left ventricular end-diastolic
olume; SEC  spontaneous echo contrast.
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Fate of High-Risk Patients With AF June 7, 2005:1807–12rteries (n  20) and deep middle cerebral arteries (n  2).
o diffusion abnormalities in border zone areas or diffuse
iffusion abnormalities were noted. Eleven (9%) of 43
atients had new MRI findings at the 1-month follow-up,
5 (12%) at the 3-month follow-up, 20 (16%) at 6-month
ollow-up, and 22 (17%) at 12-month follow-up.
Three patients developed clinically apparent neurologic
eficits and cerebral infarctions, as documented by cranial
RI, and two of these patients died from stroke. A total of
ight patients died during the observation period. Nineteen
atients had clinically unapparent cerebral embolism, as
ocumented by diffusion defects. In the control group, five
4%) had clinical silent cerebral embolism, as documented
y cranial MRI during the observation period. In the
atients with silent cerebral embolism, follow-up conven-
ional MRI was performed three months after the event, as
ocumented by cranial MRI. The patients developed a focal
ignal hyperattenuation on the T2-weighted and FLAIR
maging in the region corresponding to the original index
esion, indicating infarcted brain tissue.
arotid artery disease. Seventeen study patients had ca-
otid stenosis 50%. None of them had a cerebral lesion
uring the observation period.
nticoagulation. Eighty-eight study patients (69%) were
nticoagulated effectively at the index admission. Ten pa-
ients with effective anticoagulation at admission had a
erebral embolism during the follow-up period. During the
bservation period, the average INR was 2.3  0.3. Eighty-
ight patients (69%) were anticoagulated effectively during
he 12-month follow-up period, and 40 (31%) ineffectively.
he INR at the date of the event was 2.2 0.4. At the time
f the event, eight patients (29%) were not anticoagulated
ffectively (INR 2.0). Patients with and without effective
nticoagulation at the time of the event or during the entire
ollow-up period did not differ in terms of the incidence of
mbolic events.
able 3. Comparison of Echocardiographic Data
Study Patients
(n  128)
Controls
(n  143)
ge (yrs) 63.6  8.7 60.7  12.4
ender (male) 86 (67%) 100 (70%)
iabetes mellitus 23 (18%) 26 (18%)
ypertension 61 (48%) 82 (57%)
ean INR 2.3  0.3 2.3  0.4
AV (cm3) 116  97* 84  26*
VVD (cm3) 131  49 122  25
VEF (%) 55  16 57  13
EC (grade) 2.5  0.9† 1.4  0.5†
AAV (m/s) 0.30  0.20† 0.44  0.16†
ersistent foramen ovale (n) 12 (9%) 14 (10%)
ortic plaque 4 mm 10 (8%) 7 (5%)
ortic plaque 4 mm 86 (67%) 83 (58%)
mbolism during follow-up 28 (22%) 5 (4%)
p  0.001. †p  0.0001. Data are presented as the mean value  SD or number (%)
f patients.
INR  international normalized ratio; other abbreviations as in Table 2.
Dredictors of cerebral embolism. Patients with cerebral
mbolism had significantly lower peak emptying velocities
f the LAA (0.2  0.1 m/s vs. 0.3  0.2 m/s, p  0.001),
enser SEC (3.1 0.8 vs. 2.4 0.9, p 0.0001), and more
ommonly a positive history of thromboembolic events (9
32%] vs. 12 [12%], p  0.02). Table 3 shows the
chocardiographic data comparing patients with dense SEC
nd controls. When matching the combined end point of
mbolism and/or death and SEC degree by the Wilcoxon
igned rank test definition, there is significant concordance
p  0.0001). In Table 4, echocardiographic data compar-
ng study patients with and without embolic event during
he observation period are provided. Multivariate analysis of
therosclerotic risk factors and LV dysfunction comparing
atients with and without embolic events shows people with
n embolic event to have a higher incidence regarding these
isk factors (31 [94%] vs. 183 [77%], p  0.02). When
omparing study patients with and without an embolic
vent or patients with silent and clinically apparent embo-
ism, no significant difference in atherosclerotic risk factors
nd LV dysfunction could be found. Table 5 provides a
omparison of patients with silent and clinically apparent
mbolic events.
ISCUSSION
ne of the most important complications of AF is throm-
oembolism—in particular, cerebral embolism. It was
hown that oral anticoagulation could reduce the risk of
erebral embolism substantially (15,16). More recent studies
ave shown that patients with echocardiographic risk factors
able 4. Comparison of Echocardiographic Data
Patients With
Embolism
(n  33)
Patients Without
Embolism
(n  238)
AV (cm3) 121  52 115  11
VVD (cm3) 139  57 129  47
VEF (%) 55  18 54  15
EC (grade) 2.8  1.1* 1.8  0.8*
AAV (m/s) 0.22  0.11* 0.38  0.17*
AAV 0.2 m/s 21 (42%)* 14 (6%)*
ersistent foramen ovale 4 (14%) 8 (8%)
p  0.0001. Data are presented as the mean value  SD or number (%) of patients.
Abbreviations as in Table 2.
able 5. Patients With Primary End Points—Apparent Versus
ilent
Apparent Embolism
(n  9)
Silent Embolism
(n  19)
AV (cm3) 123  41 120  59
VVD (cm3) 152  88 131  29
VEF (%) 61  22 51  14
EC (grade) 3.1  0.9 2.6  1.1
AAV (m/s) 0.21  0.17 0.23  0.11
AAV 0.2 m/s 7 (78%) 14 (74%)
ersistent foramen ovale 0 4 (21%)ata are presented as the mean value  SD.
Abbreviations as in Table 2.
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June 7, 2005:1807–12 Fate of High-Risk Patients With AF17–19) have an elevated risk of thromboembolism. Dense
EC and low peak emptying velocities of the LAA have
een identified as important risk factors for an elevated risk
f thromboembolism (17,19). However, there are little
rospective data available on the risk of thromboembolism
n patients with SEC receiving continued oral anticoagula-
ion. Furthermore, there are no studies available assessing
he incidence of cerebral embolism serially by modern
ranial MRI techniques.
The primary finding of our study is that patients with
onvalvular AF and dense SEC have an increased risk of
linically apparent cerebral embolism or death (7%), despite
ontinued oral anticoagulation. Furthermore, our study
howed that those patients have a particularly high proba-
ility of silent cerebral embolism (15%), as assessed by serial
ranial MRI.
The finding of a 2% incidence of clinically apparent
mbolism is in accordance with the data of the Stroke
revention in Atrial Fibrillation (SPAF-III) trial (18),
emonstrating an incidence of 1.9% in patients with AF and
djusted dose warfarin. Furthermore, patients with dense
EC were identified as having an increased risk of throm-
oembolic events (17).
The mean INR level in our study cohort was 2.3, whereas
he INR level was 2.4 in the SPAF-III trial. An INR of 2.0
o 3.0, with a target INR of 2.5, is recommended by the
urrent guidelines of the American College of Cardiology
20). The data of our study raise concern as to the
ffectiveness of this approach. Whether the addition of
cetylsalicylic acid to oral anticoagulation will lower the
ncidence of cerebral embolism is debated (20). In our study,
atients did not receive additional acetylsalicylic acid. Fur-
hermore, there is concern that the addition of acetylsalicylic
cid will raise the incidence of bleeding complications
18,21).
Our finding of a high incidence of clinical silent cerebral
mbolism strengthens the assumption that patients with
EC are at a particular high risk of embolism, despite
ttempts at effective oral anticoagulation. We and other
tudy groups have previously demonstrated that cerebral
esions, as demonstrated by cerebral MRI, result in perma-
ent brain damage (8–10). This was also demonstrated in
his study.
Another important finding of our study was that patients
ith and without effective oral anticoagulation did not differ
n terms of the incidence of cerebral embolism. A possible
xplanation may be that an INR target of 2.5 was not
ufficient to prevent cerebral embolism. On the other hand,
t may also be possible that fluctuations in the level of the
NR were missed, despite serial control of INR levels, and
ower levels were associated with events. In this respect, it is
mportant to note that 15 of 22 events occurred during the
rst three months of the observation period. Because the
arget dose is adjusted during the first month, it is quite
ossible that patients with SEC are at particularly high risk
uring this period.The results of our study also demonstrate that the
ntensity of SEC and the level of the peak emptying
elocities of the LAA were predictors of cerebral embolism.
he SEC was related to a low flow phenomenon in the LA
nd its appendage. Thus, it is possible that patients with
ery dense SEC or low peak emptying velocities of the LAA
re at particularly high risk of embolism. This finding is in
oncordance with other studies showing that patients with
eak emptying velocities of the LAA 0.2 m/s or dense
EC have a high risk of embolism.
linical implications. These correlations of clinical and
EE findings support the thesis of a relationship between
A blood flow stasis and stroke risk in patients with
ermanent nonvalvular AF.
tudy limitations. The number of patients investigated
as relatively small. However, patient data were assessed on
prospective basis.
eprint requests and correspondence: Dr. Peter Bernhardt,
RT Center at the Sankt Gertrauden Hospital, Paretzer Str. 12,
0713 Berlin, Germany. E-mail: bernhardt@cardiomrt.de.
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